You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Special Topics in HR-Positive Breast Cancer

  • Authors: Erika Hamilton, MD; Komal Jhaveri, MD; Paolo Tarantino, MD; Jonathan W. Malara, PharmD, BCOP; Sarah Donahue, MPH, NP, AOCNP; Kristina Byers, PharmD, BCOP
  • CME / ABIM MOC / CE Released: 11/30/2022
  • Valid for credit through: 11/30/2023, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, pathologists, surgeons, nurse practitioners, physician assistants, pharmacists, and nurses.

The goal of this activity is for the learners to better understand the spectrum of breast cancer treatments and be able to develop strategies that translate data updates to improvements in patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Therapeutic opportunities targeting mutations of consideration in patients with HR-positive breast cancer
    • Use of antibody drug conjugates
  • Have greater competence related to
    • Managing toxicities associated with therapies used to treat HR-positive breast cancer
  • Demonstrate greater confidence in their ability to
    • Incorporate interprofessional strategies into breast cancer care


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Erika Hamilton, MD

    Director, Breast and Gynecological Cancer Research
    Sarah Cannon Research Institute/Tennessee Oncology
    Nashville, Tennessee


    Erika Hamilton, MD, has the following relevant financial relationships:
    Consultant or advisor for: Arucs; Arvinas; AstraZeneca; Black Diamond; Boehringer Ingelheim; CytomX; Daiichi Sankyo; Santari; Deciphera Pharmaceuticals; Eisai; Genentech; Greenwich LifeSciences; H3 Biomedicine; iTeos; Janssen; Lilly; Loxo; Merck; Mersana; Novartis; Orum Therapeutics; Pfizer; Propella Therapeutics; Roche; Seagen, Inc.; Silverback Therapeutics
    Research funding from: AbbVie; Accutar Biotechnology; Acerta Pharma; ADC Therapeutics; AKESOBIO; Amgen; Aravive; ArQule; Artios; Arvinas; AstraZeneca; AtlasMedx; Black Diamond; Bliss BioPharmaceuticals; Boehringer Ingelheim; Cascadian Therapeutics; Clovis; Compugen; Cullen-Florentine; Curis; CytomX; Daiichi Sankyo; Dana Farber Cancer Institute; Dantari; Deciphera; Duality Biologics; eFFECTOR Therapeutics; Ellipses Pharma; Elucida Oncology; EMD Serono; Fochon; Fujifilm; G1 Therapeutics; Genentech; H3 Biomedicine; Harpoon; Hutchinson MediPharma; Immunogen; Immunomedics; Incyte; Infinity Pharmaceuticals; InvestisBio; Jacobio; Karyopharm; Leap Therapeutics; Lilly; Lycera; Mabspace Biosciences; Macrogenics; MedImmune; Merck; Mersana; Merus; Millennium; Molecular Templates; Myraid Genetic Laboratories; Novartis; Nucana; Olema; OncoMed; Onconova Therapeutics; ORIC Pharmaceuticals; Orinove; Pfizer; PharmaMar; Pieris Pharmaceuticals; Pionyr Immunotherapeutics; Plexxikon; Radius Health; Regeneron; Relay Therapeutics; Repertoire Immune Medicine; Rgenix; Roche; Seagen, Inc.; Sermonix Pharmaceuticals; Shattuck Labs; Silverback; StemCentRx; Sutro; Syndax; Syros; Taiho; TapImmune; Tesaro; Tolmar; Torque Therapeutics; Treadwell Therapeutics; Verastem; Vincerx Pharma; Zenith Epigenetics; Zymeworks

  • Jonathan W. Malara, PharmD, BCOP

    Clinical Pharmacy Specialist: Breast Oncology ​
    The University of Texas
    MD Anderson Cancer Center ​
    Houston, Texas


    Jonathan W. Malara, PharmD, BCOP, has no relevant financial relationships.

  • Paolo Tarantino, MD

    Clinical Research Fellow ​
    Dana-Farber Cancer Institute ​
    Harvard Medical School ​
    Boston, Massachusetts


    Paolo Tarantino, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Daiichi Sankyo
    Speaker or member of speakers bureau for: AstraZeneca

  • Komal Jhaveri, MD, FACP

    Assistant Attending, Breast Medicine and Early Drug Development Service
    Section Head, Endocrine Therapy Research Program
    Clinical Director, Early Drug Development Service
    Memorial Sloan Kettering Cancer Center
    Assistant Professor
    Weill Cornell Medical College
    New York, New York


    Komal Jhaveri, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; AstraZeneca; Blueprint Medicines; Biotheranostics; Genentech; Lilly; Loxo Oncology; Novartis; Seagen, Inc.; SunPharma Pvt Ltd.; Taiho Oncology
    Research funding from: AstraZeneca; Genentech; Gilead; ImmunomedicsLilly; Loxo Oncology; Merck; Novartis; Pfizer; PUMA Biotechnology; VelosBio; Zymeworks

  • Kristina Byers, PharmD, BCOP

    Clinical Pharmacy Specialist
    Breast Oncology
    Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia


    The opinions expressed are those of Dr Byers and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Byers’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare. 
    Kristina Byers, PharmD, BCOP, has the following relevant financial relationships:
    Consultant or advisor for: Seagen, Inc.
    Speaker or member of speakers bureau for: Wellstat Therapeutics (former)

  • Sarah Donahue, MPH, NP, AOCNP

    Carol Franc Buck Breast Cancer Center
    Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco
    San Francisco, California


    Sara Donahue, MPH, NP, AOCNP, has the following relevant financial relationships:
    Consultant or advisor for: Sanofi Genzyme (former)


  • Deborah Middleton, MS

    Senior Medical Education Director, Medscape, LLC


    Deborah Middleton, MS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 1.50 contact hour(s) (1.50 CEUs) (Universal Activity Number JA0007105-0000-22-308-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Special Topics in HR-Positive Breast Cancer

Authors: Erika Hamilton, MD; Komal Jhaveri, MD; Paolo Tarantino, MD; Jonathan W. Malara, PharmD, BCOP; Sarah Donahue, MPH, NP, AOCNP; Kristina Byers, PharmD, BCOPFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/30/2022

Valid for credit through: 11/30/2023, 11:59 PM EST


A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print